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A B S T R A C T
Considerable number of intellectual disabled people experience some form of disruptive behavior. Antipsychotics are
the most common treatment for these behaviors. Numerous patients were efficiently treated with thioridazine, recently
withdrawn. The authors describe a case series of »thioridazine responders« treated with olanzapine. Thirty three patien-
ts with severe intellectual disability were recruited. All patients were assessed for seven types of disruptive behavior on fi-
ve point scale. Patients with severe behavior disturbances were included in treatment. The time points of assessment were
at day 0, 30, 60 and 180. Twenty one patient accomplished inclusion criteria. A significant decrease occurred at day 30
for all types of behavior. Total score, self injurious behavior, compulsive and destructive behavior showed further decrea-
se at day 60 and became stable until the end of study. Olanzapine appears to be efficacious in the treatment of disruptive
behavior in the intellectually disabled and could be substitute for thioridazine treatment.
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Introduction
Behavior disturbances include cluster of heteroge-
neous noncognitive symptoms and behaviors which are
not included in core features of the definition of intellec-
tual disability like behavior adaptive deficits1,2. Despite
that fact considerable number of people experiences
some of these symptoms with prevalence in communi-
ty-based population up to 60%3. These numbers are pro-
portional higher in patients with more serious disabi-
lity4. The term disruptive behavior encompasses a wide
range of behaviors that may be harmful to people or pro-
perty, may be difficult to manage and may limit access to
community facilities. Among these symptoms the most
dramatic are aggressive, self-injurious behavior and tem-
per tantrums, with range 9% to 30% and they are among
most difficult problems to treat5–8.
There is no specific treatment for disruptive behavior.
Psychotropic drugs probably have some potential to alle-
viate certain behavioral disturbances in individuals with
intellectual disability9, although there is opinion that the
suppression of problematic behavior is often achieved
largely through sedation10.
Antipsychotics are among the most widely used psy-
chotropic medication in people with intellectual disabil-
ity both for concurrent psychotic features11,12 and for dis-
ruptive behavior13. Previously the conventional antip-
sychotics were used9,13,14. One of frequently used typical
antipsychotic was thioridazine.
According to our experience and publicized data thio-
ridazine had long term usefulness for disruptive behav-
iors of institutionalized mentally retarded patients15. Be-
cause of unacceptable adverse effects, especially risk of
cardiac events thioridazine is withdrawn from approved
medications list16,17. Emerging of new, atypical antip-
sychotics with their unique 5-HT 2/D2 profile raise a ques-
tion about their efficacy in treating disruptive behaviors.
There is not clear superiority of atypical antipsychotic
over the typical in treating schizophrenic patients, but
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they did show less adverse events like extrapyramidal
symptoms, withdrawal dyskinesias and tardive dyskine-
sias18. Also typical antipsychotic may have fewer nega-
tive cognitive effects18–20.
There are some evidence about efficacy of these new
drugs in treating disruptive behaviors especially for clo-
zapine21,22, risperidone23,24 and quetiapine25. There is
some literature finding positive effects of olanzapine in
treating behavior disturbances in intellectual disability
like single case of 10-year-old autistic patient treated for
aggressive and repetitive behaviors26. Potenza at al. re-
ported an open label study of treating four children and
four adults with pervasive developmental disorder and
they found significant improvement in several domains
like aggression, hyperactivity, self-injurious behavior, ir-
ritability and anger27. Williams et al. treated 12 intellec-
tual disabled adult patients with same efficacy as risperi-
done12. Olanzapine also reduced chronic self injurious
behavior28.
According to present authors opinion, published and
available papers are still founded on small numbers of ca-
ses or case series, limited pilot studies, heterogeneous cli-
nical entities and severity of intellectual disability. Until
present time there is no robust evidence as to whether
antipsychotic medication does or does not help people
with intellectual disability and disruptive behavior.
The authors think that there is still necessity to ex-
pand available knowledge about efficacy of atypical an-
tipsychotics in treating disruptive behaviors and the aim
of present study was to evaluate that efficacy for olan-
zapine.
Methods
This was partially prospective, open label case series
report. Thirty three patients institutionalized because of
intellectual disability, disruptive behavior and absence of
appropriate family support were recruited.
Regarding ethical considerations, legal guardians
were informed about study and we have their passive
consent. All of the patients were previously treated with
conventional antipsychotic thioridazine. Olanzapine
treatment was introduced after drug free period (up to 4
months) and reevaluation of clinical condition.
The presence of only one type of three following beha-
viors: attacks to objects/damage to property, self-injuri-
ous behavior or temper tantrums were sufficient for in-
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TABLE 1
CLINICAL AND PERSONAL DETAILS FOR EACH SUBJECT
Case Age (years) Gender Co-morbidity Other medication Total score Day 0 Total score Day 180
A 12 M None 20 15
B 39 F None 17 12
C 14 F Epilepsy Carbamazepine, Clonazepam,
Valproic acid
16 14
D 14 M Epilepsy Carbamazepine, Clonazepam 12 10
E 8 M Epilepsy Phenobarbitone, Valproic acid 15 11
F 8 M Epilepsy Phenobarbitone 15 13
G 19 M Epilepsy Valproic acid 20 15
H 24 F None 11 10
I 34 F None 23 13
J 27 F None 12 10
K 20 M Epilepsy Phenobarbitone 16 10
L 14 M Epilepsy Valproic acid 16 13
M 29 M None 13 9
N 27 M None 19 14
O 15 F None 18 16
P 35 M None 22 16
R 17 M Epilepsy Clonazepam, Carbamazepine,
Lamotrigine
10 9
S 29 F None 16 12
T 25 M None 18 12
U 21 M Epilepsy Valproic acid, Carbamazepine,
Clonazepam
19 12
V 36 F None 21 14
troduction of olanzapine treatment after drug free pe-
riod. There were no other treatment modifications beside
pharmacological.
Information was collected on following parameters:
¿ socio-demographic variables (age, gender)
¿ co morbidity
¿ co therapy
¿ seven type of disruptive behaviors (attacks objects/
damage to property, self-injurious behavior, refus-
ing cooperation, temper tantrums, self-stimulation,
compulsive behavior and excessive and persistent
demands) were scored by caregivers on five point
scale (1) never and (5) always29. There was four ca-
regiver included in rating and each patient was eva-
luated by the same caregiver.
¿ Outcome of treatment as secondary variable was
measured using the global improvement and effica-
cy index measures of the clinical global impression-
-global improvement (CGI-GI) scale30. The CGI
scores were assigned by two of the investigators in-
dependently.
¿ time points of evaluation were et day 0, 30, 90, and
180
Collected data were processed by statistical software
SPPS for Windows ver. 11. descriptive statistics, Wil-
coxon test and Friedman ANOVA were used.
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TABLE 2
CAREGIVER SCORES: STATISTICAL DATA FOR EACH TYPE OF DISRUPTIVE BEHAVIOR APART AND TOTAL SCORE












































































































The review of medical documentation revealed that
thirty three patients were treated with thioridazine be-
cause of disruptive behavior. The mean duration of treat-
ment was 18 months (range 8–36 months). After with-
drawal of thioridazine the patients were followed
throughout four month »drug-free« period.
During the »drug-free« period twenty one patients
(63.6%) shown one or more inclusion disruptive behav-
iors:
¿ attacks to objects/damage to property 19 patients
¿ temper tantrums 15 patients
¿ self injurious behavior 18 patients
The mean duration of drug free period was 29.95 days
(range 6–56 days).
Among twenty-one patients which accomplished in-
clusion criteria 8 (38%) were female and 13 (62%) were
male. The mean age of the sample was 22.24 (SD 9.30),
27.25 (SD 9.25) for female and 19.15 (SD 8.19) for male.
Gender, age, co morbidity, co-therapy, total disrup-
tive behavior score at day 0 and day 180 are shown in
Table 1.
All cases fulfilled the ICD-10 criteria for severe intel-
lectual disability and were institutionalized because of
lack of adequate family assistance.
All included patient were treated with olanzapine.
Dosage range of olanzapine achieved during study period
was 5–15 mg.
The caregiver rated disruptive behaviors on the five
point scale.
Total score and scores for each individual disruptive
behavior at days 0, 30, 60 and 180 are shown in Table 2.
Total score declined statistical significantly (Wilcox-
on test) between day 0 and day 30 (p=0.000), between
day 30 and day 60 (p=0.000) and stay stable without
statistical significant change until day 180 (p= 0.15) Fig-
ure 1.
Each of seven observed disruptive behaviors shown
statistical significant decline between days 0 and 30
(p<0.05).
Two types of disruptive behavior had further decline
until day 60:
¿ Self injurious behavior (p = 0.008) Figure 2
¿ Attacks to objects/damage to property (p = 0.0039)
Figure 3
There is no statistical significant decline in total score
or individual score for any observed behaviors and that
scores stay stable between day 60 and day 180 (p>0.05).
Clinical outcome was also measured by Clinical Glo-
bal Impression-Global Improvement (CGI-GI) scale.
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Fig. 3. Caregivers score; attacks to objects/damage to property.
Fig. 1. Caregivers total scores for disruptive behaviors.
Fig. 2. Caregivers score for self injurious behavior.
The best improvement was observed in patient with
higher score. Although behavior disturbances are not in-
cluded in core features of intellectual disability they still
have remarkable influence on clinical impression and pa-
tients with higher disruptive behavior score had higher
start CGI score.
Conclusion
Behavioral symptoms in intellectual disabled people
are common and problematic in clinical practice. They
represent a significant part of the day-to-day workload of
the psychiatry team and caregivers.
The aim of the present study was to evaluate the effi-
cacy of olanzapine treatment on disruptive behaviors in
heterogeneous group of patients with severe intellectual
disability. The olanzapine is relatively new antipsychotic
medication and there is broad spectrum of new indica-
tions beside psychotic disorders waiting for eventual af-
firmation.
The use of olanzapine in treatment of disruptive be-
haviors in people with intellectual disability is not well
established.
The present authors found that olanzapine appeared
to have efficacy in reducing disruptive behavior in people
with intellectual disability and this is in accordance with
some previous findings for antipsychotics in general7–9,
for olanzapine12,14,26–28. This study of 21 patients previ-
ously treated with thioridazine indicated that olanzapine
was associated with statistical significant improvement
on five point scale and CGI scale.
Broadly evaluation on CGI scale showed that 17 pa-
tients were rated as minimally improved or better at day
180. This represents some kind of paradox where target-
ing no-core symptoms results in significant change in
perception of patient’s clinical presentation.
The study also show that even in population with se-
vere form of intellectual disability there is considerable
ratio (nearly 40%) of patients who does not need the con-
tinuous treatment with antipsychotic medication. This
finding is in accordance with some other studies of clini-
cal outcome in intellectually disabled patients with-
drawn from chronic antipsychotic medication31.
All of this supports emerging trends to establishing
regular reevaluation of antipsychotic treatment of dis-
ruptive behavior and which resulted in the development
of legislative and procedural controls in Western coun-
tries32. The sample size of our study is one of largest re-
ported with sociodemografic data somewhat different
compared with other reports (lower mean age).
Our study has number of limitation like no placebo
controls and no blinding occurred.
The evaluation of previously thioridazine response of
disruptive behaviors was retrospective. Diagnostically,
our study group was diverse because nine patients had
some form of epilepsy and were treated with anticonvul-
sive drugs.
Antipsychotic treatment of disruptive behavior in in-
tellectually disabled persons is so-called off label indica-
tion and according to authors opinion there is no interest
among producers of drugs to expand indication on this
area. Because of that the vast majority of our knowledge
about this gray zone came from studies like this with
numbers of limitation.
Further research in this area should involve and in-
clude appropriate control groups, double-blind and pla-
cebo-controlled methodology, and longitudinal follow-up.
There is need for ongoing review and for further re-
search, particularly into the reasons for use and the effi-
cacy of the drugs on target behaviors. Research needs to
be conducted to ensure that medication administered to
people with intellectual disability is appropriate in type
and level.
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U^INAK OLANZAPINA NA DISRUPTIVNO PONA[ANJE KOD INSTITUCIONALIZIRANIH
PACIJENATA SA TE[KIM INTELEKTUALNIM ONESPOSOBLJENJEM – SERIJA SLU^AJEVA
S A @ E T A K
Zna~ajan broj ljudi s intelektualnim pote{ko}ama pokazuje neki oblik disruptivnog pona{anja. Antipsihotici se naj-
~e{}e koriste u lije~enju takvog pona{anja. Znatni broj pacijenata je lije~en tioridazinom, koji je nedavno povu~en s tr-
`i{ta. Autori opisuju seriju slu~ajeva »tioridazin respondera« lije~enih olanzapinom. Trideset i tri bolesnika sa te{kim
intelektualnim pote{ko}ama uklju~ena su u studiju. Procjenjivano je sedam tipova disruptivnog pona{anja na skali od
pet stupnjeva. Uklju~eni su i bolesnici s te{kim promjenama pona{anja. Vremenske to~ke ocjenjivanja su bile na dan 0,
30, 60 i 180. Dvadeset i jedan bolesnik je zadovoljio kriterije uklju~ivanja. Zna~ajno pobolj{anje je primije}eno 30-ti dan
za sve tipove pona{anja. Ukupni zbroj, samoozlje|uju}e pona{anje, prisilno i destruktivno pona{anje pokazuju daljnji
pad 60-ti dan i ostaju stabilni do kraja studije. Olanzapin se pokazao u~inkovitim u lije~enju disruptivnog pona{anja
kod bolesnika sa intelektualnim pote{ko}ama, te bi se mogao koristiti kao zamjena za tioridazin.
S. Drmi} and Frani}: Olanzapine and Disruptive Behavior, Coll. Antropol. 32 (2008) 2: 325–330
330
